Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31336698 | 0.86 | RAB9A (0.39) | RAB9APOLBNPC1SMN1; SMN2KMT2A | |
| SCHEMBL30061569 | 0.86 | RAB9A (0.42) | RAB9APOLBNPC1SMN1; SMN2KMT2A | |
| SCHEMBL22437556 | 0.82 | SMN1; SMN2 (0.50) | RAB9APOLBNPC1SMN1; SMN2KMT2A | |
| SCHEMBL27269496 | 0.82 | RAB9A (0.48) | RAB9APOLBNPC1SMN1; SMN2KMT2A | |
| SCHEMBL25303289 | 0.79 | RAB9A (0.49) | RAB9APOLBNPC1SMN1; SMN2KMT2A | |
| SCHEMBL27269731 | 0.79 | KMT2A (0.51) | RAB9APOLBNPC1SMN1; SMN2KMT2A | |
| SCHEMBL20593138 | 0.79 | SMN1; SMN2 (0.58) | RAB9APOLBNPC1SMN1; SMN2KMT2A | |
| SCHEMBL4594309 | 0.78 | ALDH1A1 (0.40) | RAB9APOLBNPC1SMN1; SMN2KMT2A | |
| SCHEMBL22437521 | 0.77 | RAB9A (0.44) | RAB9APOLBNPC1SMN1; SMN2KMT2A | |
| SCHEMBL8308094 | 0.77 | POLB (0.59) | RAB9APOLBNPC1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106499-A1 | OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS | BIAL - PORTELA & CA., S.A. (PT) | 2026-05-21 | — | — | WO | disclosed |
| US-12599676-B2 | Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy | MyricX Pharma Limited (GB) | 2026-04-14 | — | — | US | disclosed |
| US-20260048136-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MYRICX PHARMA LTD (GB) | 2026-02-19 | — | — | US | disclosed |
| US-20260049075-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MYRICX PHARMA LTD (GB) | 2026-02-19 | — | — | US | disclosed |
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| EP-4583979-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| CN-119968369-A | Cytotoxic imidazo [1,2-a ] pyridine compounds and their use in therapy | 迈里克斯制药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |
| EP-4471029-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | Suzhou Genhouse Bio Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-20240391923-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | SUZHOU GENHOUSE BIO CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| US-9732039-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmeceuticals, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9434692-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160075660-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-03-17 | — | — | US | disclosed |
| CN-102838546-B | Pyrazole derivatives as modulators of 5-ht2a serotonin receptor useful for treatment of disorders related thereto | ARENA PHARM INC | 2015-07-15 | — | — | CN | disclosed |
| EP-2066641-B1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20130217700-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-01-07 | — | — | US | disclosed |
| CN-101611013-A | As 5-HT2APyrazole derivatives of serotonin receptor modulators for the treatment of disorders related thereto | ARENA PHARM INC (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2066641-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008042388-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2B | RAB9A 1275/4885POLB 4428/4885NPC1 1049/4885 |
| US-20130217700-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | RAB9A 1615/4885POLB 4458/4885NPC1 1012/4885 |
| US-20260049075-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | XPA, FLT3, TPMT | RAB9A 1696/4885POLB 997/4885NPC1 3497/4885 |
| US-20260048136-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | SLC7A1, FLT3, ABL1 | RAB9A 1210/4885POLB 1959/4885NPC1 2852/4885 |
| US-12599676-B2 | Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy | ABL1, FLT3, MTX2 | RAB9A 1057/4885POLB 1798/4885NPC1 3189/4885 |
| US-20240391923-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | MAT2B, MAT2A, MAT1A | RAB9A 1548/4885POLB 352/4885NPC1 3299/4885 |
| US-20160075660-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2B | RAB9A 1275/4885POLB 4428/4885NPC1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.